[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ocular-hyperemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ocular-hyperemia":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100643646","phase-3-an-investigation-of-fid-123472-ophthalmic-solution-to-vehicle-for-the-reduction-of-ocular-redness-in-adults-100643646",false,"NCT07578363","An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults","A Multicenter, Randomized, Vehicle-Controlled Evaluation of the Efficacy and Safety of FID 123472 Ophthalmic Solution for the Reduction of Ocular Redness in Adult Subjects","Key Inclusion Criteria:\n\n* Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form.\n* Willing and able to follow all instructions and attend all study visits.\n* History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion.\n* Baseline ocular redness score greater than 1 unit on a 5-point scale in both eyes prior to randomization.\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Known contraindications or sensitivity to the use of any of the study treatment(s) or their components, or any other medication required by the protocol.\n* Ocular surgical interventions within 6 months prior to Visit 1 or during the study.\n* Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study parameters.\n* Use of prohibited medications, devices, or treatments as specified in the protocol.\n* Out of range vital signs (blood pressure and\u002For pulse rate) as defined in the study protocol.\n* Abnormal intraocular pressure.\n* Other protocol-defined exclusion criteria may apply.","ALL","18 Years",{"count":19,"type":20},178,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness caused by minor eye irritations.",[26],"Ocular Hyperemia",[28],"Ocular Redness","NOT_YET_RECRUITING","2026-06-08",{"date":32,"type":33},"2026-06-10","ACTUAL",{"date":35,"type":20},"2026-09",{"date":37,"type":20},"2027-03",{"name":39,"class":40},"Alcon Research","INDUSTRY",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":52,"conditions":53,"keywords":54,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":55,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":41},"100633773","phase-3-efficacy-and-safety-of-fid-123472-ophthalmic-solution-for-ocular-redness-in-adults-100633773","NCT07531043","Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults","A Two-Arm Multicenter Clinical Trial to Investigate Efficacy and Safety of FID123472 Ophthalmic Solution Compared With Vehicle in Adult Subjects With Ocular Redness","Key Inclusion Criteria:\n\n* Capable of giving signed informed consent and comply with the requirements listed in the Informed Consent Form.\n* Willing and able to follow all instructions and attend all study visits.\n* History of redness relief eyedrop use within the last 6 months, or an interest in using over-the-counter redness relief drops, or would benefit from the use of redness relief drops in the investigator's opinion.\n* Baseline investigator-assessed ocular redness score of greater than 1 on a 5-point scale in both eyes prior to randomization on Day 1 (Visit 2).\n* Other protocol-defined inclusion criteria may apply.\n\nKey Exclusion Criteria:\n\n* Known contraindications or sensitivity to the use of any of the investigational product(s) or their components, or any other medication required by the protocol.\n* Ocular surgical intervention within 6 months prior to Visit 1 or during the study.\n* Any ocular condition that, in the opinion of the investigator, may compromise the subject's safety or study specific parameters.\n* Use of any of the prohibited medications or devices as specified in the study protocol.\n* Out-of-range vital signs (blood pressure and\u002For pulse rate) as defined in the study protocol.\n* Abnormal intraocular pressure.\n* Other protocol-defined exclusion criteria may apply.",{"count":50,"type":20},230,[23],"The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.",[26],[28],{"date":32,"type":33},{"date":57,"type":20},"2026-10",{"date":59,"type":20},"2027-02",{"name":39,"class":40}]